TY - JOUR
T1 - Is niacin ineffective? Or did AIM-HIGH miss its target?
AU - Nicholls, Stephen J.
PY - 2012/1/1
Y1 - 2012/1/1
N2 - The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.
AB - The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.
UR - http://www.scopus.com/inward/record.url?scp=84859088486&partnerID=8YFLogxK
U2 - 10.3949/ccjm.79a.11166
DO - 10.3949/ccjm.79a.11166
M3 - Article
C2 - 22219232
AN - SCOPUS:84859088486
VL - 79
SP - 38
EP - 43
JO - Cleveland Clinic Journal of Medicine
JF - Cleveland Clinic Journal of Medicine
SN - 0891-1150
IS - 1
ER -